Skip to main content

Posters

Analytical Validation of PGDx elio™ Plasma Focus Dx to Facilitate Precision Oncology Through Decentralized Liquid Biopsy for Solid Tumor Profiling

17 Nov 2023

The PGDx elio™ Plasma Focus Dx is a highly specific, sensitive, reproducible, and accurate hybrid capture-based next-generation sequencing (NGS) assay optimized for cell-free DNA with excellent performance in analytical validation studies across various variant types and solid tumor types. These results support the use of PGDx elio Plasma Focus Dx as a decentralized liquid biopsy solution for informing precision oncology decision-making.

 

Authors:

  • Jesse Fox
  • Tonya N. Watkins
  • Pengfei Gu
  • Colby Ganey
  • Cindy Maddox
  • Paul McGregor
  • Andrew Georgiadis
  • Ana Perez-Lebron
  • Nesha Jackson
  • Robert Summersgill
  • Amanda Harvey
  • Sonomi Dillon
  • Amy Meltzer
  • Vito Caropreso
  • Nobel Girmay
  • Kristy Lewis
  • James Occean
  • Steve Higgins
  • Liam Cox
  • James R. White
  • Cal Palumbo
  • David Holcomb
  • Kelly M. R. Gerding
  • Kenneth C. Valkenburg